Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Beximco Pharma`s Generic Carbidopa Receives Approval in the U.S.
JERSEY CITY, N.J., Aug. 29, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of positive results from the pivotal, Phase 3, multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial of investigational ND0612 – a continuous, 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD) – as part of the International Congress of Parkinson's Disease and Movement Disorder Society (MDS), being held in Copenhagen, Denmark, August 27-31. The study, which evaluated the efficacy, safety and tolerability of ND0612 in comparison to oral immediate-release (IR) LD/CD in people with Parkinson's disease (PD) experiencing motor fluctuations, met its primary endpoint and the first four secondary endpoints. Results, which follow positive topline data reported earlier this year, will be presented as both a poster and part of an Oral Platform Presentation at the meeting.
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
Zydus' Generic Carbidopa, Levodopa Approval in the U.S.
New Delhi: AbbVie Inc said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults and had requested more information on the device used to administer the treatment.
Enforcement Report - Week of March 8, 2023
Aurobindo's Generic Carbidopa, Levodopa Receives Approval in the U.S.
Rubicon's Generic Carbidopa, Levodopa Receives Approval in the U.S.